medical Marijuana « AGORACOM Small-cap Investor Relations Blog

Posts Tagged ‘medical Marijuana’

Enertopia Provides Burlington MMPR Update

Posted by AGORACOM-JC at 8:23 AM on Tuesday, December 9th, 2014

VANCOUVER, BC / December 9, 2014 / Enertopia Corporation (ENRT-OTCBB) (TOP-CSE) (the “Company” or “Enertopia”) is pleased to announce that Health Canada has advised the Company that the Burlington, Ontario application has advanced to the Enhanced Screening Stage of the application process.

The company is pleased to advise shareholders that its license application with joint venture partner, Lexaria Corp (LXRP), submitted for licensed producer in July 2014 is now at the Enhanced Screening process. Ontario Operations Manager Mr. Donald Shaxon is the responsible person in charge of the Burlington JV.

The Burlington Joint Venture with Lexaria Corp has applied to produce 10,000kg of Medical Marihuana per year under its Licensed Producer application. Enertopia has 51% interest in the joint venture and Lexaria Corp 49% as disclosed on April 9, 2014 in Enertopia’s press release #201424 and press release #201439.

The Burlington JV has requested a Ready to build letter from Health Canada once the application has made it through step 4 of the approval process.

For those not familiar with the Health Canada process for becoming a licensed producer, below are the levels to be reached through the application process. Note there are no specific process times for each step:

Step 1: Preliminary Screening (Completed)
Step 2: Enhanced Screening (Underway)
Step 3: Security Clearance
Step 4: Review
Step 5: Ready to build letter (if required by applicant)
Step 6: Pre-licence inspection
Step 7: Licensing

The Joint Venture (JV) has been active in the local community and has received very good community and media support. The JV also met with the local policing authority and upon licensing by Health Canada we have proposed that the local police could conduct security and swat team training at the facility. We are very pleased to be working closely with law enforcement and look forward to their insights in preventative and proactive security measures.

On November 24, 2014 Health Canada updated the number of Licensed Producers to grow and sell Marijuana to 14 and the number of Licensed Producers to grow Marijuana at 8 for a current total of 22 Licensed Producers in Canada.

“Enertopia looks forward to the next steps in the application process and receiving a letter to build in 2015. In 2015 Enertopia we will be launching education and wellness seminars to help educate the public and medical community on the responsible and educated uses of Medical Marijuana” Stated President / CEO Robert McAllister.

About Enertopia

Enertopia’s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call

Clark Kent, Media Inquiries: (647) 519-2646

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, potential licensing and financing of its medical marihuana projects, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities. There is no assurance that the Burlington Joint Venture will obtain a license under MMPR and or that the Company will receive a letter to build in 2015 or be able to obtain future financings.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: #smallcapstocks, $TSXV, CSE, medical Marijuana
Posted in Enertopia, Enertopia Corp., Medical Marijuana Stocks | Comments Off on Enertopia Provides Burlington MMPR Update

Lexaria Updates Burlington License Application

Posted by AGORACOM-JC at 8:10 AM on Tuesday, December 9th, 2014

Kelowna, British Columbia — (December 9, 2014) – Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) is pleased to announce progress on the Burlington, Ontario MMPR license application.

Health Canada has advised our joint venture partner Enertopia Corp (ENRT) that the Burlington, Ontario application has advanced to the Enhanced Screening Stage of the application process. The Burlington Joint Venture with Enertopia Corp originally applied in July 2014 to produce 10,000kg of Medical Marihuana per year under its Licensed Producer application. Enertopia has 51% interest in the joint venture and Lexaria Corp 49% as earlier released.

Health Canada has noted the following steps in processing an application. Note there are no specific process times for each step:

Step 1:	Preliminary Screening (Completed)
Step 2:	Enhanced Screening (Underway)
Step 3:	Security Clearance
Step 4:	Review
Step 5:	Ready to build letter (if required by applicant)
Step 6:	Pre-licence inspection
Step 7:	Licensing

The current application is thorough and has been considerably improved by improvements made during the Preliminary Screening process, which has now been completed. The Burlington JV has requested a Ready To Build letter from Health Canada once the application has completed step 4 of the approval process.

Lexaria thanks its managers and its consultants for their dedication and hard work in advancing the license application to date.

On November 24, 2014 Health Canada updated the number of Licensed Producers to sell Marijuana to 14 and the number of Licensed Producers to grow Marijuana at 8 for a current total of 22 Licensed Producers in Canada.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for opportunities that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana or alternative health businesses will provide any benefit to Lexaria. The Company makes no human health claims related to cannabinoids derived from any source.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: #smallcapstocks, $TSXV, CSE, medical Marijuana, otcbb stocks, THC
Posted in Lexaria Corp., Medical Marijuana Stocks | Comments Off on Lexaria Updates Burlington License Application

Mazorro Receives Conditional Approval of Change of Business and Name Change

Posted by AGORACOM-JC at 4:36 PM on Wednesday, December 3rd, 2014

OTTAWA, ONTARIO–(Dec. 3, 2014) – Mazorro Resources Inc. (the “Company“) (CSE:MZO)(FRANKFURT:JAM) announces that it has received the conditional approval of the Canadian Securities Exchange (the “CSE“) for its proposed change of business from mineral resource exploration to the medical marijuana industry (the “Change of Business“) and its change of name to “GrowPros Cannabis Inc. / Entreprise GrowPros cannabis inc.” (the “Name Change“) upon receipt of necessary shareholder approval in respect thereof and completion of the three-cornered amalgamation with GrowPros MMP Inc., previously announced on November 6, 2014 (the “Amalgamation“).

The Company has filed an updated Form 2A listing statement under its profile on the CSE website and on SEDAR at www.sedar.com that provides additional disclosure of the terms of the Amalgamation, the Company’s proposed new business, and the related risk factors.

The Company expects that the CSE will publish a bulletin shortly to announce the resumption of trading of the Company’s common shares (the “Common Shares“) on the CSE at the opening of trading on December 4, 2014. The trading symbol “MZO” will remain the same until completion of the Amalgamation and the Name Change, following which the Common Shares will trade on the CSE under the symbol “GCI”.

Completion of the Amalgamation, the Change of Business, and the Name Change, remain subject to a number of conditions, including, but not limited to, receipt of necessary shareholder approvals in respect thereof and satisfaction of standard closing conditions for transactions of this nature.

The special meeting of the Company’s shareholders that was called to seek the requisite approval for the Change of Business and the Name Change, among other items, has been postponed and will now be held on December 29, 2014 (the “Special Meeting“). A notice of meeting, management information circular, and form of proxy in respect of the Special Meeting will be sent to shareholders and is available under the Company’s profile on the CSE website and on SEDAR.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to complete the Amalgamation and Change of Business, failure to obtain sufficient financing, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Any forward-looking statement speaks only as of the date on which it is made and except as may be required by applicable securities laws. The Company disclaims any intent or obligation to update any forward-looking statement.

Mazorro Resources Inc.
Andre Audet
Interim President, CEO, and CFO
(613) 241-2332

Tags: #smallcapstocks, $TSXV, CDB, medical Marijuana, Medical Marijuana stocks, THC
Posted in GrowPros Cannabis Inc., Medical Marijuana Stocks | Comments Off on Mazorro Receives Conditional Approval of Change of Business and Name Change

INTERVIEW: Supreme (SL:CSE) Discusses Construction Progress at 342,000 SQF. Medical Marijuana Production Facility

Posted by AGORACOM-JC at 8:22 PM on Tuesday, November 25th, 2014

Supreme Discusses Progress of 342K sqf. Medical Marijuana Production Facility

WATCH INTERVIEW NOW!

Significant progress made at its 342,000 square foot greenhouse facility located in Kincardine, Ontario
Moving quickly to implement its proposed plan to produce up to 24,000,000 grams of medical marijuana
Recently completed $1.7M financing
Received conditional pre-approval letter from Health Canada

Supreme is a Canadian-owned and operated company whose mission is to enhance the quality of life for their patients and clients by producing sun-grown medical marijuana of the highest standards, quality and value. The company’s vision is a client-centered, environmentally-friendly and affordable medical marijuana marketplace sustained by the marriage of commercial agriculture and traditional growing.

Hub On AGORACOM / Corporate Profile / Watch Interview!

Tags: #smallcapstocks, $TSXV, CSE, medical Marijuana
Posted in All Recent Posts, Medical Marijuana Stocks, Supreme Pharmaceuticals Inc | Comments Off on INTERVIEW: Supreme (SL:CSE) Discusses Construction Progress at 342,000 SQF. Medical Marijuana Production Facility

Lexaria Develops Proprietary Cannabidiol Technology

Posted by AGORACOM-JC at 10:10 AM on Monday, November 24th, 2014

VANCOUVER, British Columbia, Nov. 24, 2014 (GLOBE NEWSWIRE) — A new study from Orrin Devinsky, MD, of the New York University School of Medicine, suggests that Cannabidiol (CBD) may radically reduce seizures in patients with epilepsy.

Dr. Devinsky administered cannabidiol to 23 patients with treatment-resistant epilepsy. Thirty-nine percent of the patients saw their seizure rates drop by more than 50%. Four patients (17%) had no seizures for the last month of treatment.

Lexaria (CSE:LXX) (OTCQB:LXRP) has acquired 51% of PoViva Corp, an innovative health company developing Cannabidiol (CBD)-infused products. Lexaria may increase its ownership position to 75% at a later date.

“Most CBD’s taste awful,” stated Lexaria CEO and Chairman Chris Bunka in an exclusive interview with Financial Press. “Marian Washington and Michelle Reillo â€“ the two principals at PoViva â€“ have developed patent-pending technology to bind CBD to a lipid. As well as enabling the body to process the CBDs more efficiently, this technology makes it taste much better.”

The first PoViva Tea by Lexaria will be a traditional black tea, which accounts for about 85% of all the tea consumed. Initially Lexaria will sell the CBD lipid-bound tea loosely – and then as the product line gets traction Bunka anticipates introducing flavored teas and tea bags.

In March, 2014 Lexaria entered into the medical marijuana market in Canada where it is legal federally. Its production license application is being reviewed by Health Canada.

“We continue to press for that license,” stated Bunka. “But we made an executive and board decision to build immediate value for the company pursuing opportunities in the hemp-based Cannabidiol (CBD) market – which does not require new licensing, laws or legislation.”

The Alternative Health sector is growing fast. A six year survey with 29,370 subjects monitored the adoption of “complementary and alternative medicine care professionals,” including “homeopathic, naturopathic, or herbalists.”

The study suggests that between 16.9 million and 18.5 million Americans are seeking an alternative health care professional at any given time.

“The US Department of Health has patented CBDs and claimed that they are beneficial in treating Parkinson’s, Alzheimer’s, Cancer, Cardio-vascular diseases and concussion,” stated Bunka. “An overwhelming body of research indicates that Cannabidiol has significant medicinal properties.”

Bunka sees Cannabidiol products as much more than a niche health market. There are many patients with Alzheimer’s and other diseases who don’t want to use marijuana.

Lexaria is planning to market its products to the 150 million daily tea drinkers in the United States. The market for CBDs is much larger than that of marijuana-users.

“We’re not changing focus, we’re sharpening it,” stated Bunka. “We are still in the same sector, but in a 100% legal part of it, which means we can produce foods that contain CBD and create short term cash flows for the company.”

Lexaria is in the process of launching a new e-commerce website and setting up a national distribution center, with 1-800 call ordering.

“Our marketing will include traditional media, direct marketing, and we also are building relationships with alternative health media outlets,” stated Bunka. “Some of these organizations have expressed interest in affiliate marketing campaigns so we are also exploring that.”

Bunka has a conservative approach to alternative medicine, including cannabis. The company has initiated a Responsible Marijuana Policy which states that Lexaria will not sell medical marijuana containing more than 0.3% THC to any medical marijuana patient under the age of 25.

Subsequent to Lexaria’s announcement, the College of Family Physicians of Canada created new guidelines that included the recommendation that medical marijuana in most cases would not be appropriate for patients under the age of 25.

Lexaria is currently investigating several popular food and drink sectors where its patent-pending lipid-binding Cannabidiol delivery system might prove effective. Lexaria has acquired a 3-year exclusive right to the patent-pending process to infuse CBD’s into all global markets outside of the USA.

The 2015 combined hot beverage markets of coffee and tea together, globally, is expected to be $69 Billion according to a report by Basu Majumder A., Bera B. and Rajan A.

According to the US Department of Health and Human Services Patent number 6,630,507, “Cannabidiol is particularly advantageous to use because it avoids toxicity that is encountered with psychoactive cannabinoids at high doses.”

Lexaria continues to pursue the Health Canada MMPR Licensed Producer status by way of its joint venture in Burlington Ontario with Enertopia Corp. Meanwhile Bunka is focussed on producing cash flows from new initiatives; including the CBD-sectors (like epilepsy treatment) derived from already-legal hemp.

According to the Center for Disease Control and Prevention, Epilepsy affects about 2 million people in the United States and accounts for $15.5 billion in direct costs and indirect costs.

Lexaria is currently trading at .09 with a market capitalisation of $3.1 million.

Legal Disclaimer/Disclosure: A fee has been paid for the production and distribution of this Report. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this article should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. Financial Press makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the authors only and are subject to change without notice. Financial Press assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this article and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this article.

Also, please note that republishing of this article in its entirety is permitted as long as attribution and a back link to FinancialPress.com are provided. Thank you.

CONTACT: Lexaria Corp.
         950 - 1130 West Pender Street Vancouver BC V6E 4A4
         p. 604 602 1675 f. 604 685 1602
         e. [email protected]

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: #smallcapstocks, $TSXV, CSE, medical Marijuana
Posted in Lexaria Corp., Medical Marijuana Stocks | Comments Off on Lexaria Develops Proprietary Cannabidiol Technology

Cannabis (MMJ) Goes Mainstream

Posted by AGORACOM-JC at 4:46 PM on Friday, November 21st, 2014

Vancouver, BC / November 24, 2014 / 3,500 well-dressed investors and entrepreneurs converged last week in Las Vegas in what was the marijuana industry’s biggest event to date by far – the 3rd annual Marijuana Business Conference and Expo.

It was a monumental event, bringing together some of the top agricultural companies in the country with experts in security, logistics, software, packaging, even Wall St. was there as well as several reported celebrity sightings. To say we have a very hot new sector in this country is an understatement.

Supreme Pharmaceuticals (SL-CSE) (SPRWF-OTC) is looking like a champion on this frontier, having built a high-tech pharmaceutical-grade greenhouse in Canada, ideally suited for cannabis cultivation on a large-scale.

“In May 2014 we purchased a 342,000 square foot agricultural greenhouse in Kincardine, Ontario,” stated Supremes’ Director of Operations in an exclusive interview with Financial Press, “since then we’ve deployed over $4 million dollars to convert it into a medical marijuana growing facility that exceeds the federal regulatory requirements.”

The speedy execution of the construction phase reflects the financial, entrepreneurial and operational mix of Supremes’ management team. The company has a solid track record in capital markets, logistics and the marijuana space.

In January, 2014 Supreme received a “Ready-to-Build” letter from the federal regulator indicating its proposal to produce up to 24,000 KG of medical marijuana per year met the regulatory requirements. The ready to build letter states that a producer’s license will be issued following a successful pre-licence inspection.

As the pre-license construction phase comes to a close, the company is now one step away from a green light to commercially produce medical marijuana. “Within the next few weeks we anticipate completing all of the pre-installed regulatory requirements” stated Fowler, “that means the security infrastructure, quality assurance and record keeping protocols are all in place – and we’re ready to put seeds in the ground and turn the lights on.”

Fowler describes the Kincardine greenhouse as the ideal facility to produce high quality, low cost medical marijuana, which will become one of Supremes’ cornerstone competitive advantages. In addition to the traditional cost-saving benefits of greenhouse agriculture, this greenhouse is uniquely suited to medical marijuana production. “The greenhouse is designed to be much shorter than a traditional agricultural greenhouse,” Fowler continued, “which is ideal for shorter plants like marijuana. This design means there are millions of cubic feet of air that we do not have to manage with our climate control systems. Reducing heating and cooling saves costs and boosts production efficiency.”

The size of the Kincardine facility gives Supreme a significant competitive advantage over other applicants. Health Canada’s regulatory guidance states that it intends to transform a sprawling cottage industry to a small number of scaled growing facilities. “Economies-of-scale have enabled us to make significant capital expenses with construction and quality control” said Fowler, “we’re doing premium installations that would not be practical for a 40,000 square foot facility.”

Supreme is also one of the first medical marijuana companies to take an agricultural approach to the production of medical marijuana. “This is an agricultural business first, which is why we are utilizing an agricultural facility and the latest technology for automated greenhouse agriculture” stated Fowler, “we have a large, secured, highly automated facility capable of providing a sustainable supply of a standardized medical product, something the medical community has told us is essential. One of the problems with smaller facilities is that they can run out of product, depending on the harvesting cycle. That can be a problem for patients who are only responsive to one strain. Supremes’ scale means that we can guarantee reliability and consistency in the supply chain.”

Fowler describes the biggest advantage Supreme gains from the greenhouse is the town of Kincardine itself. “The unforeseen benefit of this greenhouse facility in Kincardine had been the town itself,” stated Fowler, “We’ve got support from all levels of government, the local business community and the residents. Last Saturday we had a job fair, which was attended by over 600 locals, even though we only advertised twenty positions. That level of support is unprecedented in an industry where simply being left alone is a victory.”

Image: http://www.accesswire.com/images/322/Untitled.jpg

Fowler has been involved in the medical marijuana industry for over a decade. He’s likely the only businessman and corporate lawyer in Canada who also has extensive hands-on experience with the medical marijuana patient community and marketplace.

Fowler also intends to use his experience as a patient advocate to help Supreme attract patients who require medical marijuana to treat various ailments. “We are going to institute innovating pricing models,” stated Fowler, “designed to accommodate patients on a limited budget and mitigate the fact insurance providers do not yet cover medical marijuana.”

On November 17, 2014 Supreme closed a non-brokered private placement financing which, based on investor interest, was increased in size twice, generating $1.78 million in additional capital for the Company.

Supreme Pharmaceuticals is currently trading on the Canadian Securities Exchange at $.41 with a market cap of $31 million.

Financial Press Legal Disclaimer/Disclosure to go at end of each client article:

Also, please note that republishing of this article in its entirety is permitted as long as attribution and a back link to FinancialPress.com are provided. Thank you.

Contact Information

Investor Relations
430-580 Hornby Street, Vancouver BC
V6C 3B6 Phone: (604) 674-2191
Email:[email protected]
Website: www.supreme.com

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: #smallcapstocks, $TSXV, CSE, medical Marijuana
Posted in Medical Marijuana Stocks, Supreme Pharmaceuticals Inc | Comments Off on Cannabis (MMJ) Goes Mainstream

Enertopia Provides Footage of Planned MMPR Facility

Posted by AGORACOM-JC at 9:59 AM on Thursday, November 20th, 2014

Whitefish, MT / November 20, 2014 / Thus far there has only been a handful of companies approved by Health Canada for the MMPR program, including Tweed Inc. (TSX-V: TWD) and Organigram Inc. (TSX-V: OGI), while a number of other companies, such as Abattis Bioceuticals (OTC: ATTBF) continue to await their approvals from Health Canada.

While many publicly traded companies have been talking up their plans of becoming licensed producers, few have been very open about showing off their actual facilities and demonstrating how operations will work. Outdoor images of large warehouses and pictures of land from a mile high provide investors with very little information about what’s actually happening in these companies.

Enertopia Corp. (OTC: ENRT) recently released a four part video series in conjunction with its joint venture with The Green Canvas Ltd. After signing a joint venture agreement in February of 2014, the company has begun building and outfitting a 30,000 square foot facility – scalable to 55,000 square feet – to become compliant with Health Canada’s MMPR standards.

The video tour of the planned facility includes everything from the initial clone rooms, perimeter security, vegetative grow areas, vaults, multiple staging areas for flowering, and the lights that will be used for production.

In the overall 4 part video series, Enertopia’s management team discusses its operational plans within Canada’s rapidly growing medical marijuana industry, while also interviewing current medical marijuana patients that have been treated with the utmost compassion by Green Canvas. The Green Canvas’ history as a licensed producer under the legacy Medical Marijuana Access Regulations (“MMAR”) program also provides them with the ability to show actual current growing operations.

It is the expertise of these current operations that deserves special notice. On November 8th, 2014 the invite only Karma Cup was held to determine the best flowering varieties of marijuana for the indica, sativa, and hybrid entrants. With more than 70 entrants, the Green Canvas was awarded first place in the sativa category for their Ambrosia strain. This year the Green Canvas was also awarded first place in the Sativa category at the Prairie Medicinal Harvest Cup for the 4th year in a row, achievements that the company is very proud of since the sativa strains typically take much longer to grow, and are often times more effective at treating the medical conditions of their patients.

As well, in September the Green Canvas joint venture announced that it submitted its application to become a licensed producer, and that they are in correspondence with Health Canada regarding specific quality assurance reports. Facility upgrades are ongoing and the construction progress can be seen in the aforementioned videos, highlighting just how close the company is to bringing the planned facility to fruition.

Tim Selenski is the head grower for the Green Canvas Ltd. grow team, and has worked with the Canadian government via their MMAR program for over 10 year time. Since its involvement in the MMAR program, Green Canvas has been widely covered in the Canadian media and has become a trusted source for medical marijuana patients.

Click For More Information:

– Company Website – http://www.enertopia.com/

– CannabisFN Profile Page – http://www.cannabisfn.com/mdc/enertopia-corp/

Legal Disclaimer:

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.

Tags: #smallcapstocks, $TSXV, CBD, CSE, medical Marijuana
Posted in Enertopia, Enertopia Corp., Medical Marijuana Stocks | Comments Off on Enertopia Provides Footage of Planned MMPR Facility

Enertopia and Lexaria Launch Medical Advisory Board

Posted by AGORACOM-JC at 8:04 AM on Thursday, November 20th, 2014

Vancouver, BC / November 20 2014 / Enertopia Corporation (ENRT) on the OTCBB and (TOP) on the CSE (the “Company” or “Enertopia”) is pleased to announce that it and joint venture partner Lexaria Corp (LXRP) have launched a formal Medical Advisory Board to educate and advocate on behalf of all those who have medical needs that may be able to be met through the understanding and use of medical marijuana or through the use of cannabidiol (CBD) extracted from Industrial Hemp.

The Medical Advisory Board members specialize in various medical categories, and will work with health care professionals, patients, and prescribers of medical marijuana to promote greater understanding of medical marijuana and of CBD-enhanced products. There are believed by many to be a wide variety of medical conditions that might be affected in a positive way either by medical marijuana or by CBD’s, but in many cases the accuracy of claims may not be well understood at this time.

In particular, the use of high-cannabidiol strains that have little or no psychoactive effects on the patient, are of interest for use to treat many medical symptoms, according to existing studies and literature.

Recreational use of Marijuana is illegal in Canada, and illegal at the federal level in the United States because of the THC content; and this status has prevented and or greatly reduced the opportunity for peer-reviewed scientific study. Still, there is growing evidence that there could be real medical benefits somehow associated with either medical marijuana and/or the CBD’s within it. Despite the hurdles to conducting past research, there are 1,277 references today to Cannabidiol at research papers located at the US National Library of Medicine, National Institutes of Health website (www.pubmed.gov).

Many organizations are calling for additional research regarding medical marijuana. For instance the Arthritis Society in September announced it wants more research to study the impact of medical marijuana on pain, and that it is preparing to fund clinical studies. Jason McDougall, chair of the Arthritis Society’s scientific advisory committee and a pain researcher at Dalhousie University was quoted at that time saying, “I think it’s high time that we found something to help the 4.6-million Canadians living with arthritis and trying to do something to help”.

Enertopia hopes to announce its first meetings and/or conferences as soon as possible in this sector and the wellness sector in general as the company moves forward.

Robert McAllister, Enertopia Corporation., President & CEO said, “We are all witnessing today the emergence of grass roots movement where the patient finally comes first in all aspects of wellness.”

About Enertopia

Enertopia’s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call

Clark Kent, Media Inquiries: (647) 519-2646

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning the Advisory Medical Board. and any wellness opportunities and any positive impact on the Company, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The reader should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: #smallcapstocks, $TSXV, CBD, CSE, medical Marijuana, Medical Marijuana stocks
Posted in Enertopia, Enertopia Corp., Medical Marijuana Stocks | Comments Off on Enertopia and Lexaria Launch Medical Advisory Board

Lexaria Launches Medical Advisory Board

Posted by AGORACOM-JC at 7:58 AM on Thursday, November 20th, 2014

KELOWNA, BC / November 20, 2014 / Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) is pleased to announce that it and joint venture partner Enertopia Corp (ENRT) have launched a formal Medical Advisory Board to educate and advocate on behalf of all those who have medical needs that may be able to be met through the understanding and use of medical marijuana or through the use of cannabidiol (CBD) extracted from Agricultural Hemp.

The Medical Advisor Board members specialize in various medical categories, and will work with health care professionals, patients, and prescribers of medical marijuana to promote greater understanding of medical marijuana and of CBD-enhanced products. There are believed by many to be a wide variety of medical conditions that might be positively affected either by medical marijuana or by CBD’s, but in many cases the accuracy of claims may not be well understood at this time.

In particular, the use of high-cannabidiol strains that have little or no psychoactive effects on the patient, are of interest for to alleviate many medical symptoms, according to existing studies and literature. Lexaria has already voluntarily established its own Canadian corporate policy of being unwilling to sell medical marijuana with more than 0.3% THC content to anyone under the age of 25, in line with much of the Canadian medical community.

Recreational use of Marijuana is illegal in Canada, and illegal at the federal level in the United States because of the THC content; this status has prevented or greatly reduced the opportunity for peer-reviewed scientific study. Still, there is growing evidence that there could be real medical benefits associated with either medical marijuana and/or the CBD’s within it. Despite the hurdles to conducting past research, there are 1,277 references today to Cannabidiol at research papers located at the US National Library of Medicine, National Institutes of Health website (www.pubmed.gov).

Lexaria hopes to announce its first meetings and/or conferences as soon as possible.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for opportunities that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana or alternative health businesses will provide any benefit to Lexaria. There is no assurance that any cannabidiol-based product will be accepted into the marketplace or have any positive impact upon Lexaria Corp. There is no assurance that and cannabidiol-based product will promote, assist, or maintain any beneficial human health conditions whatsoever.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: #smallcapstocks, $TSXV, CBD, CSE, medical Marijuana, Medical Marijuana stocks
Posted in All Recent Posts, Lexaria Corp., Medical Marijuana Stocks | Comments Off on Lexaria Launches Medical Advisory Board

Enertopia Provides Media Update on Green Canvas Joint Venture

Posted by AGORACOM-JC at 8:04 AM on Tuesday, November 18th, 2014

Vancouver, BC / November 18 2014 / Enertopia Corporation (ENRT) on the OTCBB and (TOP) on the CSE (the “Company” or “Enertopia”) is very pleased to announce that Enertopia and The Green Canvas Ltd have jointly posted a four part video series on their respective websites. Green Canvas is currently in the process of applying to become a Licensed Producer pursuant to Canada’s new Marihuana for Medical Purposes Regulation (“MMPR”).

The 4 videos are about 5 min each and showcase why the use of Medical Cannabis is so important to so many people today. “No matter what city or town I have visited over the past year since entering the Medical Marijuana sector across Canada, the one recurring theme is the gratefulness from patients that Medical Cannabis has allowed many patients to regain some or most of their lives back from prescribed pain killers”, stated President CEO Robert McAllister

In a recent Globe and Mail article from October 3, 2014 it was reported that over 2,500 Canadian’s die each year from prescribed pain killers. Somewhere in Canada this year, a car accident claimed the life of someone who was taking eight different kinds of potent painkillers. We don’t know the person’s name, age, gender or even where the crash took place – just that he or she is one of the nearly 2,500 such death reports sent to Health Canada’s “adverse drug reaction” database.

Some who died took their own lives, while others had used the pills to get high. But many were people who had received a prescription from their doctor: a 49-year-old man with heart problems, a 51-year-old woman who overdosed, perhaps forgetting that her dosage had gone up, a 69-year-old man simply in “pain.” The entries are voluntary and imprecise (some deaths appear more than once), but the database is the closest the federal government comes to tracking the body count in the nation’s pitched battle with painkillers.

“For over ten years myself and The Green Canvas team have been working hard at trying to stop this madness with our ability to provide Medical Cannabis for patients in dire need of mental and physical pain relief”, stated Tim Selinski founder and President of The Green Canvas.

Robert McAllister, Enertopia Corporation., President & CEO said, “We are all witnessing today the emergence of the next great health and wellness industry of our times where the patient finally comes first.”

The youtube channel for the videos can be found at: http://www.youtube.com/user/EnertopiaCorp.

Further information on the Green Canvas can be found at www.thegreencanvas.ca/

The Company also announces the granting of 100,000 stock options at 10 cents per share for five years to a consultant to the Company.

About Enertopia

Enertopia’s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call

Clark Kent, Media Inquiries: (647) 519-2646

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning the appointment of The Green Canvas Ltd. and anticipated expertise of The Green Canvas or the MMPR application being granted by Health Canada having any positive impact on the Company, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The reader should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: #smallcapstocks, $TSXV, medical Marijuana
Posted in Enertopia Corp., Medical Marijuana Stocks | Comments Off on Enertopia Provides Media Update on Green Canvas Joint Venture

Posts Tagged ‘medical Marijuana’

Categories